+Compare
VBIV
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
14M

VBIV VBI Vaccines Forecast, Technical & Fundamental Analysis

a developer of biopharmaceuticals

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for VBIV with price predictions
07:00 PM EST Dec 05, 2023

VBIV sees its Stochastic Oscillator ascending out of oversold territory

On November 28, 2023, the Stochastic Oscillator for VBIV moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 72 instances where the indicator left the oversold zone. In of the 72 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

VBIV moved above its 50-day moving average on November 28, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for VBIV crossed bullishly above the 50-day moving average on November 27, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where VBIV advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 166 cases where VBIV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 05, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on VBIV as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VBIV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VBIV broke above its upper Bollinger Band on November 20, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.727) is normal, around the industry mean (20.710). P/E Ratio (0.000) is within average values for comparable stocks, (137.900). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.885) is also within normal values, averaging (330.425).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. VBIV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VBIV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 7%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 27%. IVBT experienced the highest price growth at 1,413%, while IBIO experienced the biggest fall at -61%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -6%. For the same stocks of the Industry, the average monthly volume growth was 2% and the average quarterly volume growth was 64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 58
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

VBIV is expected to report earnings to fall 97.83% to -7 cents per share on August 09

VBI Vaccines VBIV Stock Earnings Reports
Q2'23
Est.
$-0.07
Q1'23
Missed
by $1.55
Q4'22
Missed
by $0.01
Q3'22
Missed
by $0.01
Q2'22
Missed
by $0.02
The last earnings report on May 08 showed earnings per share of -322 cents, missing the estimate of -166 cents. With 53.74K shares outstanding, the current market capitalization sits at 14.00M.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
160 Second Street
Phone
+1 617 830-3031
Employees
196
Web
https://www.vbivaccines.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CRNT1.880.04
+2.17%
Ceragon Networks Ltd
BDC69.430.39
+0.56%
Belden
TECK36.660.04
+0.11%
Teck Resources Limited
PETZ1.30N/A
-0.01%
TDH Holdings
CENX7.38-0.30
-3.85%
Century Aluminum Company

VBIV and

Correlation & Price change

A.I.dvisor indicates that over the last year, VBIV has been loosely correlated with SRNEQ. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if VBIV jumps, then SRNEQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VBIV
1D Price
Change %
VBIV100%
+8.81%
SRNEQ - VBIV
63%
Loosely correlated
+1.87%
MDGL - VBIV
56%
Loosely correlated
+0.54%
AXON - VBIV
48%
Loosely correlated
+0.27%
ONCT - VBIV
44%
Loosely correlated
+10.24%
CYTK - VBIV
44%
Loosely correlated
+2.67%
More

Groups containing VBIV

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VBIV
1D Price
Change %
VBIV100%
+8.81%
drugs
(undefined stocks)
28%
Poorly correlated
+1.33%
biopharmaceuticals
(undefined stocks)
27%
Poorly correlated
+1.86%
biotechnology
(undefined stocks)
26%
Poorly correlated
+1.71%